Allergan Shares Fall After CEO Says Two Studies Delayed

Allergan Inc., the maker of the Botox wrinkle treatment, fell the most in 13 years after saying it will delay final studies for drugs to treat age-related macular degeneration and baldness.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.